Head-to-head comparison
Peter MD vs Science & Co
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
A physician-prescribed telehealth brand pairing GLP-1 tirzepatide and compounded semaglutide+B12 with TRT, sermorelin, NAD+, hair-loss and ED care on one account — tirzepatide from $249/mo, semaglutide+B12 from $149/mo.
$149/mo (first month only) sema · $249/mo (quarterly prepay) tirz · Verified August 2026
Marked down on: Tirzepatide steps up after month one — $149 for the first month, then $249/mo billed quarterly
Desk Score
Answers the question most sellers here never raise — it states in its own footer that it is not a compounding facility — and explains its own asterisk in its own FAQ.
$149/mo sema · $199/mo tirz · Verified September 2026
Marked down on: The number it leads with is a twelve-month commitment; the per-month rates are $149 and $199.
Peter MD takes this head-to-head with the higher Desk Score, 77/100 (C+) against 76/100 (C) for Science & Co. Science & Co still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Peter MD
77/100
C+
Science & Co
76/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Peter MD | Science & Co |
|---|---|---|
| Semaglutide | $149/mofirst month only$149/mo (GLP1+B12, compounded, first-time tier; $139/mo returning-patient tier) | $149/mo$149/mo month-to-month (compounded; $79 only on a 12-month plan) |
| Tirzepatide | $249/moquarterly prepay$249/mo (60mg, billed quarterly; $149 first month) | $199/mo$199/mo month-to-month (compounded; $125 only on a 12-month plan) |
| Coverage | Most states (restrictions vary by treatment — excludes several, incl. AL, ID) | Not listed on Science & Co's site (checked September 2026) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes. | A twelve-month committer, or anyone who values a company stating plainly what it is and is not. |
| Desk Score | 77/100C+ | 76/100C |
The verdict
Desk pick — Peter MDPeter MD takes this head-to-head with the higher Desk Score, 77/100 (C+) against 76/100 (C) for Science & Co. Science & Co still holds its ground where its strengths line up with yours.
Choose Peter MD if…
Patients who want GLP-1 care alongside TRT, NAD+, sermorelin or other men's-health treatments under one physician-guided account, and don't need brand-name or oral routes.
$149/mo (first month only) sema · $249/mo (quarterly prepay) tirz · Most states (restrictions vary by treatment — excludes several, incl. AL, ID)
Choose Science & Co if…
A twelve-month committer, or anyone who values a company stating plainly what it is and is not.
$149/mo sema · $199/mo tirz
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Peter MD · Science & Co.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Peter MD
- CoreAge Rx vs Science & Co
- Ondra Health vs Peter MD
- Ondra Health vs Science & Co
- Peter MD vs Tyde Wellness
- Science & Co vs Tyde Wellness
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.